CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.

The market has been buzzing with attention highlighting the latest from Dendreon Corporation (NASDAQ:DNDN). The company that brought the world the prostate cancer treatment Provenge has continued to miss the target on estimated revenues while blowing through millions in cash. In a U.S. Bankruptcy Court filing on Monday, Dendreon listed more than $664 million in total debts and $364.6 million in assets. According to several reports, the Company will look to first sell itself to a buyer that would keep producing Provenge but if it receives no qualifying bids, the debt holders will convert their debt to equity and take over Dendreon making it a private company.

Dendreon's stock price has plummeted from a previous close on Friday of $0.9421 to a low of $0.1738 Monday afternoon. Market sentiment appears bleak heading into the week ahead as uncertainties continue to surround this most recent announcement. What was supposed to be the Company's champion product has essentially become its downfall. Analysts had first expected Provenge to bring in billions after its 2010 launch. Unfortunately this was a cart before the horse situation as the company built up its debt in anticipation of the drug's release. Once the curtains opened, it was a completely different story and Dendreon fell short of its expectations. Speculation abounds as to a new buyer coming up to the plate but one thing's for sure, this won't be the last we hear on the topic.

Advanced Cell Technologies (OTC:ACTC) also fell short of expectations but is actually the hidden "breakout" in today's overview. Though the recent quarter compares almost identical to the same quarter last year, the Company's nine-month results show an entirely different tale of the tape. Revenues declined significantly by more than 35% due to license agreements that expired in 2013. But despite these results, the company's stock has seen a glimmer of hope after rebounding 13% from last week's low of $6.20. Analysts on sites like Seeking Alpha speculate that it's because of the Company's successful results in Phase 1 trials, which set Advanced Cell above others in its class.

Now for the "bust"; Fuse Sciences (OTC:DROP) has unfortunately fallen victim to its own ticker symbol after drop-ping 98.77% since announcing its restructuring plans for "expanding on its operations". Back in October the Company highlighted its acquisition of renewable energy monitoring company, Spiral Energy Technology, Inc. and ubsequent to this, Fuse filed an 8-K whereby its original directors resigned. At the same time Spiral CEO Ezra Green and director Dr. Gelvin Stevenson were appointed as directors of Fuse. Does this mean Fuse is changing its model from biotech to alternative energy? Since these two developments were formalized, there has been little from the Company and we can only speculate that this could be a reason for the stock's recent decline.

The facts remain that the biotech space has incredible potential but even companies with unique products can fail if the business is mismanaged. This is an important piece for investors to pay attention to. As with Dendreon, the Company has a one of a kind prostate cancer treatment but it can't stay afloat. Yet on the other hand, you have a company like Fuse who's previous CEO was featured earlier this year on Bloomberg alongside Daymond John for the company's novel method of energy and electrolyte product delivery. Even Tiger Woods was a supporter of the Company's technology but yet it appears Fuse is completely bowing out of the biotech space. . Even though Advanced Cell fell short of 9-month earnings, the market has taken a liking to the stock and price has benefited this week. For investors it would make sense to do the utmost in due diligence when deciding on the right investment in such a large industry in order to stay out of the cross-hairs of a potential bankruptcy or bust situation.

For More articles like this please Subscribe Here: http://www.DailyStockReporter.com/

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts.

Subscribe Here: http://www.DailyStockReporter.com/

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. EGM FIRM INC which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Contact Information

Adam Heimann
info@egmfirm.com


SOURCE: DailyStockReporter,com